BioInvent International AB

Biotechnology ResearchSkåne, Sweden51-200 Employees

BioInvent International AB is a clinical-stage biotechnology company that discovers and develops immuno-modulatory antibodies for cancer therapy. Its pipeline includes five drug candidates across six Phase 1/2 clinical programs addressing hematological cancers and solid tumors. The company relies on its proprietary F.I.R.S.T technology platform to identify therapeutic targets and the antibodies that bind them, generating candidates for internal development and for licensing partnerships. It also runs a fully integrated manufacturing unit that produces antibodies for third parties.

Headquartered in Lund, Skåne, Sweden, BioInvent operates as a mid-sized biotechnology firm with active collaboration with pharmaceutical companies. In 2024 it entered a clinical supply agreement with AstraZeneca to provide Calquence for a combination trial, illustrating ongoing industry partnerships.

Sign up for free to view info

Email Format Employee directory